BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke – Odessa American

Spread the love

BioTime Announces Publication of Positive Preclinical Results Utilizing Proprietary HyStem® Platform in Ischemic Stroke Odessa American

ALAMEDA, Calif.–(BUSINESS WIRE)–Dec 4, 2018–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative …

…read more

Source:: Alameda, California News By Google News

Start a Conversation

[ghozylab-instagram feed=26796]